Actively Recruiting
Proximal Gastrectomy vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy
Led by Guihua Wang · Updated on 2026-04-27
404
Participants Needed
1
Research Sites
252 weeks
Total Duration
On this page
Sponsors
G
Guihua Wang
Lead Sponsor
F
Fudan University
Collaborating Sponsor
AI-Summary
What this Trial Is About
We plan to evaluate the efficacy and safety of proximal gastric vs. total gastric radical resection after SOX combined with anti-PD-1 neoadjuvant therapy in locally advanced upper gastric cancer
CONDITIONS
Official Title
Proximal Gastrectomy vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients voluntarily consent to participate and can comply with the study requirements
- Age between 18 and 75 years at consent
- Histologically or cytologically confirmed locally advanced upper gastric adenocarcinoma (cT3-4 or N+M0) according to AJCC 8th edition
- Tumor assessed as resectable or potentially resectable and patient consents to neoadjuvant therapy
- No previous systemic treatment for current gastric cancer, including chemo, radiotherapy, or immunotherapy
- ECOG performance status 0 or 1
- Expected survival of 6 months or more
- Preoperative chest, abdominal, and pelvic CT or PET-CT excluding distant metastasis
- Adequate major organ function meeting specific blood, liver, kidney, coagulation, and heart function criteria
- Fertile patients must use contraception during and 120 days after study and have a negative pregnancy test within 7 days before enrollment
- Non-lactating status
You will not qualify if you...
- Patients not able or unwilling to give informed consent or comply with study
- Outside age range 18 to 75 years
- Histology other than locally advanced upper gastric adenocarcinoma or tumor not resectable
- Prior systemic treatment for current gastric cancer
- ECOG performance status above 1
- Expected survival less than 6 months
- Evidence of distant metastasis on imaging
- Major organ dysfunction not meeting specified blood, liver, kidney, coagulation, or heart function thresholds
- Pregnancy, lactation, or inadequate contraception use
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tongji Hospital, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430030
Actively Recruiting
Research Team
G
Guihua Wang
CONTACT
L
lisheng chen
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here